Travere Therapeutics
TVTX
TVTX
170 hedge funds and large institutions have $1.54B invested in Travere Therapeutics in 2022 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 55 increasing their positions, 67 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less ownership
Funds ownership: →
10% less capital invested
Capital invested by funds: $1.7B → $1.54B (-$162M)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
18% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 67
Holders
170
Holding in Top 10
7
Calls
$4.14M
Puts
$1.91M
Top Buyers
| 1 | +$15.7M | |
| 2 | +$15.5M | |
| 3 | +$14.2M | |
| 4 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$11.9M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$10.8M |
Top Sellers
| 1 | -$30.9M | |
| 2 | -$18.8M | |
| 3 | -$16.8M | |
| 4 |
Millennium Management
New York
|
-$15.8M |
| 5 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$15.3M |